Compare CAC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CAC | ANL |
|---|---|---|
| Founded | 1875 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.1M | 731.6M |
| IPO Year | 1996 | 2022 |
| Metric | CAC | ANL |
|---|---|---|
| Price | $50.13 | $11.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $47.00 | $20.00 |
| AVG Volume (30 Days) | 77.4K | ★ 182.3K |
| Earning Date | 04-28-2026 | 04-10-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $41,739,000.00 | N/A |
| Revenue This Year | $19.15 | $36.02 |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $38.62 | ★ N/A |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $35.00 | $0.88 |
| 52 Week High | $53.71 | $17.25 |
| Indicator | CAC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 47.32 |
| Support Level | $47.12 | $11.86 |
| Resistance Level | $51.57 | $12.09 |
| Average True Range (ATR) | 1.07 | 1.34 |
| MACD | 0.21 | -0.25 |
| Stochastic Oscillator | 77.44 | 29.71 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.